| Statins impair antitumor effects of rituximab by inducing conformational changes of CD20 M Winiarska, J Bil, E Wilczek, GM Wilczynski, M Lekka, PJ Engelberts, ... PLoS medicine 5 (3), e64, 2008 | 159 | 2008 |
| Cardiotoxicity of the anticancer therapeutic agent bortezomib D Nowis, M Mączewski, U Mackiewicz, M Kujawa, A Ratajska, ... The American journal of pathology 176 (6), 2658-2668, 2010 | 157 | 2010 |
| Primary mediastinal large B-cell lymphoma A Dabrowska-Iwanicka, JA Walewski Current hematologic malignancy reports 9 (3), 273-283, 2014 | 60 | 2014 |
| Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity J Bil, M Winiarska, D Nowis, K Bojarczuk, A Dabrowska-Iwanicka, ... Blood, The Journal of the American Society of Hematology 115 (18), 3745-3755, 2010 | 60 | 2010 |
| Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice. WS Golab J, Stoklosa T, Czajka A, Dabrowska A, Jakobisiak M, Zagozdzon R ... Anticancer Res. 2000 May-Jun;20(3A):1717-21, 2000 | 51* | 2000 |
| Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)Polish compassionate use experience GW Basak, W Knopinska-Posluszny, M Matuszak, E Kisiel, D Hawrylecka, ... Annals of hematology 90, 557-568, 2011 | 45 | 2011 |
| First‐line R‐CVP versus R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by
J Walewski, E Paszkiewicz‐Kozik, W Michalski, G Rymkiewicz, T Szpila, ... British journal of haematology 188 (6), 898-906, 2020 | 29 | 2020 |
| Hematología T Robak, K Warzocha Via Medica, 2016 | 26 | 2016 |
| Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies M Winiarska, K Bojarczuk, B Pyrzynska, J Bil, M Siernicka, M Dwojak, ... MAbs 6 (5), 1300-1313, 2014 | 22 | 2014 |
| Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor A Sureda, C Chabannon, T Masszi, D Pohlreich, C Scheid, C Thieblemont, ... Bone marrow transplantation 55 (3), 613-622, 2020 | 16 | 2020 |
| Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial. E Zucca, A Davies, I Kryachok, G Ciccone, L Ceriani, B Botto, ... Journal of Clinical Oncology 41 (17_suppl), LBA7505-LBA7505, 2023 | 9 | 2023 |
| Augmented antitumour effects of combination therapy with TNP-470 and chemoimmunotherapy in mice A Dabrowska-Iwanicka, D Olszewska, A Jalili, M Makowski, T Grzela, ... Journal of cancer research and clinical oncology 128, 433-442, 2002 | 9 | 2002 |
| Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation B Ostrowska, A Szymczyk, M Olszewska-Szopa, J Romejko-Jarosińska, ... Leukemia & Lymphoma 62 (12), 3031-3034, 2021 | 8 | 2021 |
| DLBCL: Who is high risk and how should treatment be optimized? AP Dabrowska-Iwanicka, GS Nowakowski Blood Journal, blood. 2023020779, 2023 | 6 | 2023 |
| High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up J Romejko-Jarosinska, B Ostrowska, A Dabrowska-Iwanicka, ... Scientific Reports 12 (1), 10551, 2022 | 6 | 2022 |
| Treatment of primary mediastinal B-cell lymphoma-a multicenter retrospective analysis on behalf of the Polish Lymphoma Research Group A Dąbrowska-Iwanicka, A Giza, W Jurczak, A Polakiewicz-Gilowska, ... Annals of Oncology 22 (suppl. 4), 2011 | 6 | 2011 |
| R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International
G Held, B Altmann, A Kerkhoff, T Gastinne, T Weber, RO Casasnovas, ... Blood 142, 435, 2023 | 2 | 2023 |
| S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37
M Martelli, L Ceriani, E Zucca, I Kryachok, G Ciccone, U Ricardi, B Botto, ... HemaSphere 7, e2454568, 2023 | 2 | 2023 |
| A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPY AJ Davies, E Zucca, L Ceriani, I Kryachok, G Ciccone, B Botto, ... Hematological Oncology 41, 48-50, 2023 | 2 | 2023 |
| Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R‐MIV) in patients with primary CNS lymphoma including
B Ostrowska, K Domanska‐Czyz, J Romejko‐Jarosinska, M Osowiecki, ... British Journal of Haematology 201 (4), 663-672, 2023 | 2 | 2023 |
